Tag: AbbVie
Humira Generic Delay Case Against AbbVie, Amgen, Sandoz Appealed
AbbVie, Amgen (a Samsung subsidiary), and Novartis unit Sandoz will face an appeal to the Seventh Circuit of antitrust claims over patent infringement settlements...
AbbVie Dodges Antitrust Challenge to Its Humira ‘Patent Thicket’
AbbVie Inc., Amgen Inc., a Samsung subsidiary, and Novartis unit Sandoz Inc. don’t have to face antitrust claims over patent infringement settlements that delayed generic competition for the blockbuster arthritis drug...
AbbVie Antitrust Case Atty Now Manager at FTC
Federal Trade Commission attorney Patty McDermott, who led the agency’s 2018 antitrust trial against pharmaceutical giant AbbVie Inc., is now a manager at the...
AbbVie Wins US Antitrust OK To Buy Allergan
AbbVie won US antitrust approval for its acquisition of Botox maker Allergan, clearing the last hurdle from competition regulators to the $63 billion deal.
The Federal...
AbbVie, Allergan Merger May Face Delay Due To COVID-19
With the final hurdle for their $63 billion merger cleared in the EU, AbbVie and Allergan were in the home stretch to close the deal....
AbbVie Gets Final EU Approval for Allergan Buy
As part of US biopharma major AbbVie’s $6.3 billion acquisition of Ireland-incorporated Allergan announced…
To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial...
AbbVie-Allergan $63B Deal Aided By Nestle Buy
US drugmaker AbbVie’s $63 billion tie-up with Allerganis getting help from Nestle and AstraZeneca buying up products the Irish-domiciled company is shedding to placate regulators.
According...
US: Allergan to shed two drugs for AbbVie deal
Allergan has confirmed that it will divest experimental inflammatory bowel disease therapy brazikumab and marketed drug Zenpep ahead of its US$63 billion acquisition by...
US: AbbVie to Buy Allergan for $63B
US drugmaker AbbVie has agreed to buy Allergan, the Irish-domiciled maker of Botox, in a US$63 billion that is the sector’s latest blockbuster transaction...
US: AbbVie hit with antitrust lawsuit over Humira “patent thicket”
AbbVie used a dense web of 100-plus patents to insulate its blockbuster drug Humira from US competition while cutting deals with rivals that delayed...
